Danazol for the treatment of idiopathic thrombocytopenic purpura.
Idiopathic thrombocytopenic purpura is an autoimmune disorder, most common in young women. We treated 22 patients with this disorder (12 of whom were women) with danazol, an androgen with reduced virilizing capability, for two months or longer. Fifteen had undergone splenectomy, all were receiving glucocorticoids, and 18 had also been given other treatments. Fifteen of the patients were benefited, 11 with sustained normalization of their platelet counts. Six of eight patients tested had initial increases in circulating platelet-reactive IgG; in all six there was a marked decrease concomitant with danazol therapy. Danazol was effective in both men and women, irrespective of previous treatments. The duration of remissions ranged from 2 to 13 months. The drug was well tolerated and appears to be better suited than glucocorticoids for long-term management of idiopathic thrombocytopenic purpura, but the exact indications for the use of danazol in this disorder remain to be determined.
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D001792:Blood Platelets / Q000276:immunology; D003613:Danazol / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011245:Pregnadienes / Q000627:therapeutic use*; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000276:immunology; D013156:Splenectomy
D001323:Autoantibodies; D011245:Pregnadienes; D003613:Danazol